Quick Takeaways
- Clovis Oncology, Inc. has 16 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Insider Transactions Reported by 16 Insiders of Clovis Oncology, Inc.
- Location
- Boulder, CO
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Clovis Oncology, Inc. executives and other stock owners filed with the SEC include:
Top shareholders of Clovis Oncology, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Gillian Ivers-Read |
3/4/5
|
Executive Vice President of Technical Operations and Chief Regulatory Officer |
—
mixed-class rows
|
316,737
mixed-class rows
|
$288,591 | — | 01 Nov 2022 | |
| Lindsey Rolfe |
3/4/5
|
Officer |
—
mixed-class rows
|
136,816
mixed-class rows
|
$111,747 | — | 01 Nov 2022 | |
| Daniel W. Muehl |
3/4/5
|
Executive Vice President and Chief Financial Officer |
—
mixed-class rows
|
127,955
mixed-class rows
|
$103,037 | — | 01 Nov 2022 | |
| Paul Edward Gross |
3/4/5
|
Executive Vice President and General Counsel |
—
mixed-class rows
|
121,455
mixed-class rows
|
$96,649 | — | 01 Nov 2022 | |
| Thomas C. Harding |
3/4/5
|
Senior Vice President and Chief Scientific Officer |
—
mixed-class rows
|
33,258
mixed-class rows
|
$22,890 | — | 01 Nov 2022 | |
| Ronit Simantov |
3/4/5
|
Director |
—
class O/S missing
|
83,212
|
— | — | 12 Jul 2021 | |
| Patrick J. Mahaffy |
3/4/5
|
President and Chief Executive Officer, Director |
—
class O/S missing
|
80,000
|
— | — | 01 Mar 2022 | |
| BLAIR JAMES C |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Brian G. Atwood |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Edward J. McKinley |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Flaherty Keith T. |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Ginger L. Graham |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Paul H. Klingenstein |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Richard A. Fair |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Robert Azelby |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 | |
| Thorlef Spickschen |
3/4/5
|
Director |
—
class O/S missing
|
42,223
|
— | — | 10 Jun 2021 |
Recent Insider Transactions by Companies or Individuals for Clovis Oncology, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.